MDACC Study No:2012-0697 ( NCT No: NCT01751425)
Title:Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia (CML) with Minimal Residual Disease While on Therapy with Tyrosine Kinase Inhibitors
Principal Investigator:Jorge Cortes
Treatment Agent:Ruxolitinib
Study Status:Open
Study Description:This is a 2 part study. The goal of the first part of this clinical research
study is to find the highest tolerable dose of ruxolitinib that can be given
with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib)
as part of your standard of care treatment. The goal of the second part of
this study is to learn if this drug combination can help to control CML.
Although you have a good response to therapy, the disease is still detectable
at low levels (this is called "minimal residual disease"). Researchers believe
that eliminating all detectable evidence of disease may decrease the chances
that the leukemia will ever come back. The safety of the drug combination will
also be studied in both parts.

Ruxolitinib is designed to block a protein called Jak2 that may help keep some
leukemia cells alive even with TKI therapy. Blocking this protein may cause
the cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Ruxolitinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Incyte Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults